文献速递甲状腺疾病

CCDC149-ALK融合病例报告:转移性甲状腺乳头状癌中的新遗传改变与临床相关靶点

Case Report of CCDC149-ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2022-11-21

本文报告一例30岁女性转移性放射性碘难治性甲状腺乳头状癌患者,经下一代测序检出既往未在甲状腺乳头状癌中描述的CCDC149-ALK融合。患者接受阿来替尼治疗后8周内可触及病灶完全消退,血清甲状腺球蛋白大幅下降,再分期影像显示客观部分缓解。作者建议对BRAFV600E阴性放射性碘难治性甲状腺乳头状癌进行深度突变测序以识别可靶向遗传改变。

要点

  • CCDC149-ALK为新发现的甲状腺乳头状癌ALK融合。
  • 阿来替尼治疗8周内可触及病灶完全消退,甲状腺球蛋白大幅下降。
  • 再分期影像显示客观部分缓解。

核心结论

  • 本病例强调ALK融合在甲状腺癌中的作用及其在甲状腺乳头状癌中的临床意义。

研究设计与样本

  • 病例报告:一例30岁女性转移性放射性碘难治性甲状腺乳头状癌患者,经下一代测序检出CCDC149-ALK融合。

主要发现

  • 患者为30岁女性,存在肺、肌肉和脑的进展性广泛转移性放射性碘难治性疾病。
  • 经下一代测序检出既往未在甲状腺乳头状癌中描述的CCDC149-ALK融合。
  • 患者开始接受第二代间变性淋巴瘤激酶(ALK)抑制剂阿来替尼治疗。
  • 治疗8周内可触及病灶完全消退,血清甲状腺球蛋白大幅下降。
  • 再分期影像显示客观部分缓解。

临床怎么用

  • 作者建议对BRAFV600E阴性放射性碘难治性甲状腺乳头状癌进行深度突变测序,以识别包括基因融合在内的可靶向遗传改变,这些改变可能带来显著治疗获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, usually with an indolent course. ALK fusions are rare in PTC but may give rise to a more aggressive behavior. We report a novel ALK fusion, CCDC149-ALK, not previously described in PTC, detected by next-generation sequencing in a 30-year-old woman with progressive widely metastatic radioiodine-refractory (RAIR) disease to lung, muscle, and brain. The patient was started on alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor. Within eight weeks, her palpable disease had completely regressed, and the serum thyroglobulin decreased dramatically. Restaging imaging demonstrated an objective partial response. Our case highlights the role of ALK fusions in thyroid cancer and highlights its clinical significance in PTC. We recommend deep mutational sequencing in BRAFV600E-negative RAIR PTC to identify targetable genetic alterations, including gene fusions, that may result in dramatic therapeutic benefits.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee H, Krishnan V, Wirth LJ, et al. Case Report of CCDC149-ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma. Thyroid. 2022. PMID: 36150036. doi:10.1089/thy.2022.0389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。